Core Insights - Bavarian Nordic A/S has secured a new order worth USD 22.5 million from the Public Health Agency of Canada for its mpox and smallpox vaccine, MVA-BN, under a 10-year contract established in 2022 [1][6] - The company has achieved approximately DKK 1,400 million in orders for its Public Preparedness business in 2026, reflecting an increase of DKK 100 million compared to previous communications, with full-year guidance remaining at DKK 1,800-2,000 million [2] - The CEO of Bavarian Nordic emphasized the importance of public preparedness in Canada and the company's commitment to supporting government efforts against health threats like mpox and smallpox, highlighting collaborations with the US and EU [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, serving as a preferred supplier of mpox and smallpox vaccines to governments [5] - The MVA-BN vaccine is the only non-replicating mpox vaccine approved in multiple regions, including the U.S., Canada, and the EU, originally developed to ensure smallpox vaccination for the entire population, including immunocompromised individuals [4]

Core Viewpoint - Bavarian Nordic has entered into an exclusive agreement with Eurofarma to sell and distribute its chikungunya vaccine, CHIKV VLP, in Brazil, with potential expansion to the rest of Latin America [1][8] Group 1: Agreement Details - The agreement is based on transfer pricing and royalties, with no upfront or milestone payments involved [2] - Eurofarma will be responsible for seeking and maintaining regulatory approval for the vaccine in the exclusive territories, as well as covering sales and distribution costs [2] - Bavarian Nordic will continue to manufacture the vaccine, which will be provided to Eurofarma under a transfer pricing agreement [2] Group 2: Regulatory and Market Launch - The regulatory submission is expected to occur in the first half of 2026, depending on discussions with the Brazilian health authority, Anvisa, potentially supporting the vaccine's launch in Brazil in the second half of 2027 [3] - The partnership aims to improve access to chikungunya vaccines in Brazil, which accounts for half of all reported cases and related deaths globally [4][7] Group 3: Vaccine Information - CHIKV VLP is a single-dose, recombinant vaccine designed to provide active preventive immunization against chikungunya virus disease for individuals aged 12 and older [5] - The vaccine is non-infectious as it contains no viral genetic material, allowing a broad group of individuals to benefit from vaccination [6] - It was approved by the U.S. FDA and the European Commission in February 2025, and in the UK in May 2025 under the name VIMKUNYA [6] Group 4: Company Background - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines [8] - Eurofarma, founded in 1972, is a leading pharmaceutical company in Brazil, operating in 24 countries and producing 600 million units in 2024, with a net revenue of over USD 1.78 billion [10]

Core Insights - Bavarian Nordic A/S has entered into an agreement with Eurofarma for exclusive rights to sell and distribute its chikungunya vaccine, CHIKV VLP, in Brazil, with potential expansion to the rest of Latin America [1][8] - The agreement is based on transfer price and royalty, with Eurofarma responsible for regulatory approval and distribution costs, while Bavarian Nordic will manufacture the vaccine [2][5] - Regulatory submission to the Brazilian Health Regulatory Agency, Anvisa, is anticipated in the first half of 2026, aiming for a vaccine launch in Brazil by the second half of 2027 [3][4] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, including mpox and smallpox vaccines, and has a strong portfolio of travel vaccines [9] - Eurofarma, founded in 1972, is a leading Brazilian pharmaceutical company with operations in 24 countries and a significant presence in Latin America, having produced 600 million units in 2024 and achieving net revenue exceeding USD 1.78 billion [10] Vaccine Details - CHIKV VLP is a single-dose, prefilled, adjuvanted VLP recombinant protein vaccine designed for individuals aged 12 and older, with protective immunity developing as early as one week post-vaccination [5][6] - The vaccine is non-infectious, containing no viral genetic material, making it safe for a broad range of individuals [6] Disease Context - Chikungunya is a mosquito-borne disease that has emerged in over 110 countries, with Brazil accounting for more than half of the nearly 500,000 reported cases and over 200 deaths worldwide in 2025 [7] - The disease often presents with severe symptoms, and a significant percentage of patients may develop chronic symptoms lasting months or years [7]

Summary of GeoVax Labs Conference Call Company Overview - **Company Name**: GeoVax Labs - **Ticker Symbol**: GOVX - **Location**: Smyrna, Georgia - **Focus Areas**: Infectious diseases, oncology, and vaccines [1][3] Key Points and Arguments Investment Thesis - GeoVax has multiple clinical stage programs with potential revenue generation within the next three to four years [4][19] - The company has transitioned from a preclinical stage to phase two and is now moving directly to phase three for certain products, which is considered a de-risked approach [4][10] Upcoming Catalysts - **GEO-MVA**: A modified vaccinia Ankara vaccine that has been granted an expedited development path, allowing it to skip phase one and two trials and go directly to an immunobridging trial [10][11] - The trial is expected to start in the second half of the year, with a quick readout anticipated [11] - There is a significant global demand for the vaccine, particularly in Africa, which requires 25 million doses annually, while the current supplier can only provide 2 to 5 million doses [11][12] COVID-19 Vaccine Development - **GEO-CM04S1**: A multi-antigen vaccine against COVID-19 that has completed three phase 2 clinical trials [12][13] - The trials include comparisons against mRNA vaccines, with promising interim results indicating better performance than Pfizer's vaccine in certain patient populations [14][15] Oncology Focus - **Gedeptin**: A gene therapy for solid tumors, particularly head and neck cancers, showing improved performance when combined with Keytruda [17][18] - Plans for a phase 2 trial are underway, with the potential for accelerated regulatory pathways based on interim results [18][30] Manufacturing and Supply Chain - The company is working on improving the manufacturing process for MVA to increase supply and reduce costs [20][21] - A new continuous cell line method is being developed to streamline production [20] Financial Needs and Strategy - Annual capital needs are estimated at $30-$35 million, with recent fundraising efforts only covering a small portion of this requirement [19][31] - The company is exploring non-dilutive funding and strategic partnerships to reduce reliance on equity financing [31] Additional Important Information - GeoVax holds over 130 patents across 22 families, indicating a strong intellectual property position [22] - The competitive landscape includes a focus on breaking the monopoly held by Bavarian Nordic in the MVA market, which reported over $400 million in sales in 2024 [26] - The company is actively engaging with global health organizations like WHO and the International Vaccine Institute to drive its initiatives forward [12][23] Conclusion GeoVax Labs is positioned to capitalize on significant opportunities in the vaccine and oncology markets, with a focus on innovative multi-antigen approaches and expedited regulatory pathways. The company is addressing critical public health needs while navigating financial challenges through strategic partnerships and improved manufacturing processes.

Market Performance - U.S. equities are showing mixed to slightly lower performance in early trading on January 7th, 2026, following a robust rally that saw major indexes close at record highs [1] - The Dow Jones Industrial Average (DJIA) surged 0.99% to close at an all-time high of 49,462.08, while the S&P 500 (SPX) climbed 0.62% to 6,944.81, and the Nasdaq Composite (IXIC) advanced 0.65% to 23,547.17 [2] - Early Wednesday, S&P 500 futures were down slightly, and the Cboe Volatility Index (VIX) saw a slight increase, indicating a modest uptick in investor apprehension [2] Economic Data - The ADP employment report for December showed 41,000 private sector jobs created, below the consensus estimate of 45,000, indicating a softer labor market [4] - Upcoming economic indicators include the critical December nonfarm payrolls report on January 9th, the Consumer Price Index (CPI) for December on January 13th, and the Producer Price Index (PPI) for November on January 14th [5] Federal Reserve Outlook - The Federal Open Market Committee (FOMC) is scheduled to meet on January 27-28, 2026, with expectations for one or two more interest rate cuts in 2026, possibly in April and September [6] Company-Specific Movements - Energy stocks were impacted by U.S. intervention in Venezuela, with Chevron (CVX) falling more than 4%, while Valero Energy (VLO) climbed 1% due to potential benefits from access to Venezuela's oil supplies [9] - AI-related stocks, including Amazon (AMZN), Micron Technology (MU), and Palantir Technologies (PLTR), saw strong performances, with Micron gaining around 10% and Palantir increasing more than 3% [10] - American International Group, Inc. (AIG) shares plunged 7.5% after CEO Peter Zaffino announced his resignation, while Seagate Technology Holdings plc (STX) shares soared 14% amid a rally in storage stocks [11] - Merck (MRK) completed its acquisition of Cidara Therapeutics, strengthening its respiratory portfolio [12]

Core Viewpoint - Bavarian Nordic A/S has initiated a share buy-back program with a total budget of DKK 500 million for 2026, starting with a first tranche of DKK 150 million aimed at adjusting the capital structure [1][2]. Group 1: Share Buy-Back Program Details - The share buy-back program is authorized by the annual general meeting held on April 9, 2025, and complies with EU regulations on market abuse [2]. - The program will be managed by Nordea, which has been appointed as the lead manager to execute the buy-back independently [3]. - The buy-back will commence on January 7, 2026, and is expected to be completed by February 13, 2026, with a maximum of 1,500,000 shares to be repurchased [7]. Group 2: Transaction Terms - The maximum aggregate purchase price for the first tranche is DKK 150 million, and the maximum number of shares that can be purchased on any single trading day is limited to 25% of the average daily trading volume over the preceding 20 trading days [7]. - Prior to the program, Bavarian Nordic held 966,845 treasury shares, which is 1.22% of the company's share capital [5].

Group 1 - Bavarian Nordic announced the appointment of Anne Louise Eberhard as the new chairperson of the board and Heidi Hunter as the new vice-chairperson [1] - Heidi Hunter has over 25 years of experience in the pharmaceutical industry, having held leadership positions at Cardinal Health, UCB, Boehringer Ingelheim, IQVIA, and Centocor, among others [2] - In addition to her role as vice-chairperson, Heidi Hunter is a member of the Nomination and Compensation Committee and the Science and Technology Committee [3] Group 2 - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines, including mpox and smallpox vaccines [4]

Core Viewpoint - Bavarian Nordic A/S has announced a one-time share buy-back program of up to DKK 500 million to be executed over the next 12 months, reflecting a strong cash position and positive cash flow from operations [1][2]. Financial Position - As of September 30, 2025, Bavarian Nordic reported securities, cash, and cash equivalents totaling DKK 2,978 million, with approximately DKK 800 million earmarked for deferred payments to GSK and related royalties and taxes [2]. - The company believes that the cash balance after the buy-back program will be sufficient to maintain operational flexibility in an uncertain environment [2]. Share Buy-back Program Details - The shares bought back will be held as treasury stock to adjust the company's capital structure [3]. - The program will be executed in accordance with the authorization from the general meeting of shareholders and will comply with safe harbour regulations [3]. - Further details regarding the key terms of the program will be provided following the Board of Directors' final decision to launch the program [3]. Treasury Shares - Currently, Bavarian Nordic holds 966,845 shares as treasury shares, which represents 1.22% of the company's share capital [4]. - A portion of these treasury shares will be utilized to meet the company's obligations related to long-term share-based incentive programs for the Board of Directors and Executive Management [4]. Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines, including mpox and smallpox vaccines, and has a strong portfolio of travel vaccines [5].

Core Points - Bavarian Nordic A/S is hosting a shareholder meeting on December 11, 2025, to discuss the state of business and recap the company's strategy [1] - The meeting will take place at Tivoli Hotel & Congress Center in Copenhagen from 09:00 am to 10:30 am CET and will be conducted in English [1] - Shareholders must register in advance via the company's shareholder portal by December 9, 2025, due to limited seating [2] - Admission cards will be sent via email upon registration and must be presented at the meeting [3] - A recording of the meeting will be available on the company's website after the event [3] - Shareholders unable to attend can submit questions via email to be addressed during the meeting [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines [4] - The company is a preferred supplier of mpox and smallpox vaccines to governments, enhancing public health preparedness [4] - Bavarian Nordic also has a leading portfolio of travel vaccines [4]

Financial Data and Key Metrics Changes - Total revenues reached EUR 127 million for the nine months ended September 30, 2025, representing a growth of almost 9% compared to EUR 112.5 million in the same period of 2024 [4][16] - Product sales increased to EUR 119.4 million, up 6.2% from EUR 112 million in the first nine months of 2024 [14] - Operating loss reported at EUR 53.9 million compared to an operating profit of EUR 34.2 million in the prior year, primarily due to the sale of a priority review voucher in the previous year [18] Business Line Data and Key Metrics Changes - IXIARO sales reached EUR 74.3 million, increasing 12.5% year-over-year, driven by sales to the U.S. Department of Defense and increased sales in some European countries [14] - Ducoral sales decreased from EUR 22.3 million to EUR 21.5 million, impacted by foreign currency fluctuations and lower sales during the transition to a new distributor in Germany [14][15] - Exchange sales significantly increased to EUR 7.6 million from EUR 1.8 million, including the supply of doses to combat a chikungunya outbreak [15] Market Data and Key Metrics Changes - The company is focusing on expanding into low- and middle-income countries (LMICs) and new territories for IXIARO, leveraging its differentiated product profile [20][21] - The Lyme disease vaccine, VLA15, is expected to be a major growth driver, with regulatory submissions anticipated in 2026 and a potential launch in autumn 2027 [20][31] Company Strategy and Development Direction - The company aims to achieve sustainable profitability post-approval and commercialization of the Lyme disease vaccine, which is seen as a significant growth catalyst [20][21] - Valneva is actively identifying new opportunities for its R&D pipeline, aiming to build a coherent strategy for future vaccine candidates [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming Lyme disease vaccine data, which is expected to be a pivotal moment for the company [20][37] - The company is focused on reducing cash burn and ensuring sufficient runway to reach key inflection points, with cash at September 30 reported at EUR 143.5 million [18][19] Other Important Information - The company successfully completed debt refinancing, enhancing financial flexibility [5] - Research and development expenses increased to EUR 59.7 million, partly due to costs related to the Shigella vaccine candidate [17] Q&A Session Summary Question: Timeline for FDA response regarding exchange - Management indicated there is no predefined process for the FDA response and hopes for a collaborative interaction [24][25] Question: Impact of currency and distributor shift on Ducoral sales - Management noted that the transition to a new distributor in Germany caused a technical delay in purchases, but growth for Ducoral is expected to continue [25][26] Question: Timing for Lyme phase 3 readout - Management stated that Pfizer controls the process and is taking steps to ensure an early readout, with no major delays anticipated [27][28] Question: Remedies proposed to FDA for exchange BLA suspension - The response to the FDA focused on medical evidence and positive risk-benefit ratios, with ongoing pharmacovigilance reviews [29] Question: Launch timeline for VLA15 - Management confirmed that timelines communicated by Pfizer support a launch in the autumn of 2027, contingent on regulatory submissions next year [30][31] Question: Funding considerations for Zika vaccine candidate - Management highlighted uncertainty around funding and regulatory pathways, indicating that substantial funding would be necessary to proceed with development [33][36]